---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Adoptive T Cell Therapy Products Produced Using a Pharmacological p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor"
date: 2026-02-05 19:08:46 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-06128
original_published: 2024-03-22 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Adoptive T Cell Therapy Products Produced Using a Pharmacological p38 Mitogen-Activated Protein Kinase (MAPK) Inhibitor

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 22, 2024 00:00 UTC
**Document Number:** 2024-06128

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Poolbeg Pharma (UK) Limited, incorporated in the United Kingdom.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/22/2024-06128/prospective-grant-of-an-exclusive-patent-license-adoptive-t-cell-therapy-products-produced-using-a)
- API: https://www.federalregister.gov/api/v1/documents/2024-06128

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
